encorafenib,binimetinib,cetuximab,irinotecan
pfizer,eli lilly
see a subanalysis of the phase 3 beacon crc trial evaluating the effect of age on survival, qol &amp; safety in patients with previously treated braf v600e-mutant #mcrc at #wcgic2022 so-37 
Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ